








DANSKE KRÆFTFORSKNINGS DAGE 2026

Decentral behandling og digital monitorering i individualiseret hæmatologisk kræftbehandling




Thomas Lund, ledende overlæge, seniorforsker, Post Doc, lektor, Hæmatologisk Afdeling, Sygehus Lillebælt – Vejle Sygehus, Center for Innovativ Medicinsk Teknologi (CIMT), Hæmatologisk afdeling X, OUH og Institut for Regional Sundhedsforskning, Syddansk Universitet
Thomas.lund2@rsyd.dk



Udfordringer (for os) ?




Vigtige udfordringer







Med flex trafik

Bortezomib self-administration at Home




No doses lost
No patients called on the "emergency phone"




Daratumumab Provided at Home


C Unplanned contacts after treatment at the hospital



D Unplanned contacts after treatment at home



- Administered without unplanned contacts
- Contact to GP or private specialist
- Contacts related to treatment
- Contacts for unknown reasons
- Contacts to the department regarding infection
- Contacts to the department for other reasons




INTERNATIONAL MYELOMA FOUNDATION

CHMP-EMA Approves Darzalex (Daratumumab) as First Self-administered Oncology Injectable for Patients or Caregivers

App styret behandling



Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma





Gennemsnitlig alder 64 år (range 47–82). Den ældste var 82

Det tog 5,9 minutter for spl at opsætte app samt 6,13 minutter at oplære patienterne

App styret behandling



325 ud af 318 spørgeskemaer blev udfyldt. De ældre var significant bedre end de yngre til at huske det ($p = 0.015$)



www.centerforhjemmebehandling.dk

```

graph TD
    A[Treat @ Home] --> B[Head of program  
Kristina Norakov1,2]
    A --> C[Coordinating Secretary  
Charlotte Erlund1,2]
    A --> D[International expert]
    A --> E[Interdisciplinary management group  
Kristina Norakov, Ben Husted Nielsen,  
Tine Rosenberg, Camilla Thim Damgaard,  
Helle Enggaard, Thomas Lund]
    A --> F[National experts  
Kristina Norakov1,  
Rosenberg2,  
Rasmussen3,4, Jørgen  
Damgaard5,6, Trine  
Ben Husted Niels  
Kjeldsen1,3, Mary  
Enggaard1,2, Anne  
Teitboil1,3,4]
    A --> G[Pa  
Rita O. Christensen  
Lymphoma  
Carsten Levin]
  
```




The organizational chart for the Norwegian Centre for Violence and Trauma Studies (NCVTS) is structured as follows:

- Treat @ Home** (Central Hub)
 - Head of program**: Kristina Norakov^{1,2}
 - Coordinating Secretary**: Charlotte Erlund^{1,2}
 - International expert**
 - Interdisciplinary management group**: Kristina Norakov, Ben Husted Nielsen, Tine Rosenberg, Camilla Thim Damgaard, Helle Enggaard, Thomas Lund
 - National experts**: Kristina Norakov¹, Rosenberg², Rasmussen^{3,4}, Jørgen Damgaard^{5,6}, Trine Ben Husted Niels Kjeldsen^{1,3}, Mary Enggaard^{1,2}, Anne Teitboil^{1,3,4}
 - Pa**: Rita O. Christensen, Lymphoma, Carsten Levin

Work package 1	Work package 2	Work package 3	Work package 4
STUDY 1: Home-based treatment for patients with hemostasiological cancer in Denmark – a RCT Primary investigator: Kristina Nørhøj	STUDY 4: Feasibility, Safety, and Health Economic Evaluation of Home-Based Dexamethasone Treatment in Patients with Hemostasiological Cancer Primary investigator: Thomas Lind Ph.D. student: Tue Kousgaard	STUDY 3: Barriers and Facilitators to Home-Based Treatment with Dexamethasone: A Qualitative Study of Perspectives From Patients, Caregivers, and Healthcare Professionals Primary investigator: Thomas Lind Ph.D. student: Tue Kousgaard	STUDY 2: Exploring the Experience and Perspectives of Patients with Hemostasiological Cancer on Home-Based Treatment: A Qualitative Study Primary investigator: Kristina Nørhøj Research assistant Jennie Kjødkgaard
STUDY 2: Home-based chemotherapy treatment in patients with hemostasiological cancer – a systematic review Primary investigator: Kristina Nørhøj Ph.D. student: Christina Lambie	STUDY 4: SCLCA – Self-administered painkillers demonstrated in patients with multiple myeloma Primary investigator: Thomas Lind Ph.D. student: Tue Kousgaard	STUDY 3: Barriers and Facilitators to Home-Based treatment with Cytarabine: A Qualitative Study of Perspectives From Patients, Caregivers, and Healthcare Professionals Primary investigator: Kristina Nørhøj Ph.D. student: Christina Lambie	STUDY 2: Home-Based Treatment for Hemostasiological Malignancies: Experience and Perspectives of Patients and Caregivers Primary investigator: Kristina Nørhøj
STUDY 2: Research agenda for patients with hemostasiological malignancies and their caregivers Primary investigator: Tue Kousgaard Research assistant Camilla Dingsgaard	STUDY 2: Feasibility, Safety, and Health Economic Evaluation of Home-Based Cytarabine Treatment in Patients with Acute Leukemia Primary investigator: Kristina Nørhøj Ph.D. student: Christina Lambie		

Focus: [Clinical trials, Immunotherapy, Supportive and survivorship care in Myeloma]

Decentral behandling og digital monitorering i individualiseret hæmatologisk kræftbehandling



Step 1



Step 2



Step 3



© dsk

